Introducing 

Prezi AI.

Your new presentation assistant.

Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.

Loading…
Transcript

A Psycho- Pharmacological Patient Teaching Tool on Caplyta Medication

By

Ifeoma Ibenegbu

Drug

Classification

Lumateperone (Caplyta)

Medication

Atypical anti-psychotic Medication

Clinical Significance

Psychiatric & Neurological disorders

Lumateperone (Caplyta) is a first-in-class selective and simultaneous modulator of serotonin, dopamine, and glutamate. Lumateperone received its first global approval in December 2019, here in the USA for the treatment of schizophrenia in adults (Correll et al., 2021).

Side Effects and Precautions

.Extreme tiredness or fatigue

.Weight gain, nausea, dry mouth

.Dizziness, rash, hives

.Itching problems with coordination or increased falls unusual movements of your face or body that you cannot control

.Sore throat, fever, chills, or other signs of infection, fever; stiff muscles; sweating; confusion; sweating; or fast, pounding, or irregular heartbeat tightening of neck muscles or throat; or difficulty breathing or swallowing, seizures (Correll et al., 2021).

On-Label Use/ Dosage: Lumateperone 42mg is taken by mouth with food once daily around the same time, it comes as a capsule (Calabrese et al., 2021). The patient is instructed to follow the directions on the prescription label/pharmacist to explain, as prescribed by the doctor.

The Physiologic Action of the Medications

It works by changing the activity of certain natural substances in the brain which is adjusting serotonin and dopamine levels in the brain (Calabrese et al., 2021).

CAPLYTA can help improve bipolar depressive symptoms, and it's:

One pill

Once a day

Taken with or without food

No titration

Lumateperone (Caplyta) received its first global approval in December 2019, here in the USA for the treatment of schizophrenia in adults.

Schizophrenia

The Cause

Mechanism of action

Why is this

happening

Why is this happening?

The Effect

Indication for Use

How is this happening

How is this

happening?

The Solution

Side Effects and

Precautions

Off Label Use

Let's Fix it

Let's

Fix it!

References

References

Correll, C. U., Vanover, K. E., Davis, R. E., Chen, R., Satlin, A., & Mates, S. (2021). Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophrenia Research, 228, 198–205. https://doi.org/10.1016/j.schres.2020.12.006

Lumateperone. (2022). AHFS Consumer Medication Information, 1. Calabrese, J. R., Durgam, S., Satlin, A., Vanover, K. E., Davis, R. E., Chen, R., Kozauer, S. G., Mates, S., & Sachs, G. S. (2021). Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. American Journal of Psychiatry, 178(12), 1098–1106. https://doi-org.umassglobal.idm.oclc.org/10.1176/appi.ajp.2021.20091339

Lumateperone improves depressive symptoms in bipolar disorder in a new study. (2022). Brown University Psychopharmacology Update, 33(1), 1–3. https://doi-org.umassglobal.idm.oclc.org/10.1002/pu.30814

Learn more about creating dynamic, engaging presentations with Prezi